Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19566073 | 0.77 | KCNJ1 (0.47) | ACHEHCRTR1HCRTR2KCNJ1KCNH2 | |
| SCHEMBL18196008 | 0.77 | HCRTR1 (0.56) | ACHEHCRTR1HCRTR2KCNJ1KCNH2 | |
| SCHEMBL19564471 | 0.77 | KCNJ1 (0.44) | ACHEHCRTR1HCRTR2KCNJ1CYP3A4 | |
| SCHEMBL2200286 | 0.74 | KCNJ1 (0.44) | ACHEHCRTR1HCRTR2KCNJ1KCNH2 | |
| SCHEMBL16856481 | 0.72 | HCRTR1 (0.52) | HCRTR1HCRTR2KCNJ1PDE4D | |
| SCHEMBL6431761 | 0.71 | BRD4 (0.30) | — | |
| SCHEMBL6431756 | 0.71 | BRD4 (0.30) | — | |
| SCHEMBL31162811 | 0.70 | ACHE (0.53) | ACHEKCNJ1CYP3A4PDE4D | |
| SCHEMBL78687 | 0.70 | ACHE (0.53) | ACHEKCNJ1CYP3A4PDE4D | |
| SCHEMBL4963310 | 0.70 | ALOX5 (0.45) | ACHEKCNJ1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168426-A1 | NOVEL PROCESSES FOR THE PRODUCTION OF USEFUL INTERMEDIATES | IPSEN/S.C.R.A.S. (ANDRE BOURGOUIN) (FR) | 2010-07-01 | — | — | US | disclosed |
| US-7705155-B2 | Processes for the production of useful intermediates | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2010-04-27 | — | — | US | disclosed |
| US-20090247563-A9 | Novel Processes for the Production of Useful Intermediates | IPSEN/S.C.R.A.S. (ANDRE BOURGOUIN) (FR) | 2009-10-01 | — | — | US | disclosed |
| US-20070167475-A1 | Novel Processes for the Production of Useful Intermediates | IPSEN/S.C.R.A.S. (ANDRE BOURGOUIN) (FR) | 2007-07-19 | — | — | US | disclosed |
| EP-1794127-A1 | NOVEL PROCESSES FOR THE PRODUCTION OF USEFUL INTERMEDIATES | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006033011-A1 | NOVEL PROCESSES FOR THE PRODUCTION OF USEFUL INTERMEDIATES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167475-A1 | Novel Processes for the Production of Useful Intermediates | PGD, TALDO1, COASY | ACHE 4130/4885HCRTR1 4816/4885HCRTR2 4795/4885 |
| US-20090247563-A9 | Novel Processes for the Production of Useful Intermediates | PGD, TALDO1, COASY | ACHE 4130/4885HCRTR1 4816/4885HCRTR2 4795/4885 |
| US-20100168426-A1 | NOVEL PROCESSES FOR THE PRODUCTION OF USEFUL INTERMEDIATES | PGD, TALDO1, COASY | ACHE 4130/4885HCRTR1 4816/4885HCRTR2 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.